IL138345A - Composition comprising eprosartan and its use in the preparation of medicaments for blocking angiotensin ii receptors and for treating hypertension, congestive heart failure and renal failure - Google Patents

Composition comprising eprosartan and its use in the preparation of medicaments for blocking angiotensin ii receptors and for treating hypertension, congestive heart failure and renal failure

Info

Publication number
IL138345A
IL138345A IL13834599A IL13834599A IL138345A IL 138345 A IL138345 A IL 138345A IL 13834599 A IL13834599 A IL 13834599A IL 13834599 A IL13834599 A IL 13834599A IL 138345 A IL138345 A IL 138345A
Authority
IL
Israel
Prior art keywords
eprosartan
composition
preparation
salt
medicament
Prior art date
Application number
IL13834599A
Other languages
English (en)
Other versions
IL138345A0 (en
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of IL138345A0 publication Critical patent/IL138345A0/xx
Publication of IL138345A publication Critical patent/IL138345A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
IL13834599A 1998-03-11 1999-03-11 Composition comprising eprosartan and its use in the preparation of medicaments for blocking angiotensin ii receptors and for treating hypertension, congestive heart failure and renal failure IL138345A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7766098P 1998-03-11 1998-03-11
PCT/US1999/004651 WO1999045779A1 (fr) 1998-03-11 1999-03-11 Compositions a base d'eprosartan

Publications (2)

Publication Number Publication Date
IL138345A0 IL138345A0 (en) 2001-10-31
IL138345A true IL138345A (en) 2004-12-15

Family

ID=22139347

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13834599A IL138345A (en) 1998-03-11 1999-03-11 Composition comprising eprosartan and its use in the preparation of medicaments for blocking angiotensin ii receptors and for treating hypertension, congestive heart failure and renal failure

Country Status (21)

Country Link
EP (1) EP1061803B1 (fr)
JP (1) JP2002506010A (fr)
KR (1) KR20010041796A (fr)
CN (1) CN1299235A (fr)
AT (1) ATE508633T1 (fr)
AU (1) AU757547B2 (fr)
BR (1) BR9908691A (fr)
CA (1) CA2323363C (fr)
CY (1) CY1111738T1 (fr)
CZ (1) CZ303067B6 (fr)
DK (1) DK1061803T3 (fr)
ES (1) ES2366394T3 (fr)
HU (1) HU228574B1 (fr)
IL (1) IL138345A (fr)
NO (1) NO331207B1 (fr)
NZ (1) NZ506700A (fr)
PL (1) PL192545B1 (fr)
SI (1) SI1061803T1 (fr)
TR (1) TR200002646T2 (fr)
WO (1) WO1999045779A1 (fr)
ZA (1) ZA991922B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69633222T2 (de) 1995-02-24 2005-09-08 Elan Pharma International Ltd. Nanopartikel-dispersionen enthaltende aerosole
IL140905A0 (en) * 1998-07-20 2002-02-10 Smithkline Beecham Corp Bioenhanced formulations comprising eprosartan in oral solid dosage form
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
IL152081A0 (en) * 2000-04-12 2003-05-29 Novartis Ag Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
EP1382334A1 (fr) * 2002-07-11 2004-01-21 Université de Picardie Jules Verne Utilisation d'un agent bloquant du récepteur AT1 de l'angiotensine II, seul ou combiné avec un thiazide ou l'angiotensine II dans le traitement des accidents vasculaires cérébraux
US20060210620A1 (en) * 2003-01-21 2006-09-21 Kumra Pannanchukunnath M Co-precipitated amorphous losartan and dosage forms comprising the same
RS20050590A (en) 2003-01-31 2007-09-21 Sankyo Company Limited, Medicine for prevention of and treatment for arteriosclerosis and hypertension
BRPI0512379A (pt) * 2004-06-23 2008-03-11 Solvay Pharm Gmbh composições farmacêuticas compreendendo inibidores de nep, inibidores do sistema de produção de endotelina endógena e antagonista do receptor at1
US20060099230A1 (en) * 2004-11-10 2006-05-11 Chin-Chih Chiang Novel formulations of eprosartan with enhanced bioavailability
WO2006136916A2 (fr) * 2005-06-20 2006-12-28 Glenmark Pharmaceuticals Limited Particules micronisees sensiblement pures de telmisartan et compositions pharmaceutiques renfermant celles-ci
KR100715355B1 (ko) * 2005-09-30 2007-05-07 주식회사유한양행 프란루카스트를 함유하는 분무-건조 과립 및 그의 제조방법
US8361507B2 (en) * 2007-07-25 2013-01-29 Hetero Drugs Limited Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan
EP2108365A1 (fr) * 2008-04-09 2009-10-14 LEK Pharmaceuticals d.d. Formule pharmaceutique à dosage simple comportant du mesylate d'eprosartan
CN103705510A (zh) * 2013-12-27 2014-04-09 华润赛科药业有限责任公司 一种阿齐沙坦固体组合物的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
JPS587609B2 (ja) 1979-06-17 1983-02-10 フロイント産業株式会社 粉体薬剤のコ−テング法
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
JP2642486B2 (ja) 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2250395C (fr) 1996-03-29 2005-09-06 Smithkline Beecham Corporation Dihydrate d'eprosartan, procede de fabrication et formulation
KR100508044B1 (ko) * 1997-08-06 2005-08-17 스미스클라인 비참 코포레이션 에프로사르탄 아르기닌 전하-중화-복합체와 그의 제조 및제형화 방법

Also Published As

Publication number Publication date
NO20004502D0 (no) 2000-09-08
HU228574B1 (en) 2013-04-29
CN1299235A (zh) 2001-06-13
SI1061803T1 (sl) 2011-09-30
DK1061803T3 (da) 2011-08-29
JP2002506010A (ja) 2002-02-26
PL343411A1 (en) 2001-08-13
EP1061803A4 (fr) 2007-12-26
CY1111738T1 (el) 2015-10-07
AU2890999A (en) 1999-09-27
HUP0101243A3 (en) 2005-09-28
AU757547B2 (en) 2003-02-27
NO20004502L (no) 2000-11-07
ATE508633T1 (de) 2011-05-15
EP1061803A1 (fr) 2000-12-27
WO1999045779A1 (fr) 1999-09-16
NO331207B1 (no) 2011-10-31
ZA991922B (en) 1999-09-13
PL192545B1 (pl) 2006-11-30
CA2323363A1 (fr) 1999-09-16
CZ303067B6 (cs) 2012-03-21
CZ20003288A3 (cs) 2001-03-14
EP1061803B1 (fr) 2011-05-11
TR200002646T2 (tr) 2001-01-22
IL138345A0 (en) 2001-10-31
KR20010041796A (ko) 2001-05-25
ES2366394T3 (es) 2011-10-19
CA2323363C (fr) 2008-09-30
NZ506700A (en) 2003-03-28
HUP0101243A1 (hu) 2002-05-29
BR9908691A (pt) 2000-12-26

Similar Documents

Publication Publication Date Title
EP1039909B1 (fr) Procede de preparation et composition d'une preparation orale d'itraconazole
CA2338256C (fr) Formulations bioameliorees comprenant de l'eprosartane dans des formes galeniques solides destinees a une administration orale
JP2022510732A (ja) ニロチニブの医薬組成物
US20020098241A1 (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture
EP1061803B1 (fr) Compositions a base d'eprosartan
EP0889880B1 (fr) Dihydrate d'eprosartan, procede de fabrication et formulation
KR20160113294A (ko) 안드로겐 수용체 길항제의 고체 제약 조성물
EA015108B1 (ru) Способ получения твердой фармацевтической композиции, содержащей валсартан
KR101931489B1 (ko) 칼슘 길항약／안지오텐신 ｉｉ 수용체 길항약 함유 의약 제제의 제조 방법
CA2310028C (fr) Formes posologiques orales a forte dose medicamenteuse et a liberation immediate et modifiee et leurs procedes de fabrication
US20030022928A1 (en) Novel compositions of eprosartan
JP6141580B2 (ja) ラノラジンおよびドロネダロンの医薬組成物
US11260055B2 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
JP2009538905A (ja) 感湿性薬物を含んで成る安定性製剤及びその製造方法
MXPA00008888A (en) Novel compositions of eprosartan
ZA200406553B (en) Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazoloÄ1,5-bÜpyridazine in nanoparticulate form.
MXPA00006574A (en) Method and composition of an oral preparation of itraconazole

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees